What’s New Health Canada? Jan 2017

By Amelie Rodrigue-Way, Ph.D., RAC (CAN), Associate Director, Regulatory Strategy, and Christine Straccini, B.Sc., Regulatory Associate; Cato Research Canada

 

What’s New in:

Therapeutic Products Directorate:

http://www.hc-sc.gc.ca/dhp-mps/prodpharma/update-miseajour/index-eng.php

Biologics and Genetic Therapies Directorate:

http://www.hc-sc.gc.ca/dhp-mps/brgtherap/update-miseajour/index-eng.php

Medical Devices: http://www.hc-sc.gc.ca/dhp-mps/md-im/update-miseajour/index-eng.php

Natural and Non-prescription Health Products Directorate: http://www.hc-sc.gc.ca/dhp-mps/prodnatur/new-neuf-eng.php

 

 

Health Canada New Guidance Documents (Drugs and Biologics):

October – December 2016

 

Health Canada Guidance/Notice

Type

Date Posted
Updated – Guidance Document: Preparation of Regulatory Activities in the “Non-eCTD Electronic-Only” Format

http://www.hc-sc.gc.ca/dhp-mps/prodpharma/applic-demande/guide-ld/ctd/gd_prep_non_ectd_ld-eng.php

Guidance

14 Dec 2016
Guidance Document: Information and Submission Requirements for Biosimilar Biologic Drugs

http://www.hc-sc.gc.ca/dhp-mps/brgtherap/applic-demande/guides/biosimilars-biosimilaires-eng.php

Guidance

02 Dec 2016
Patented Medicines (Notice of Compliance) Regulations

http://www.hc-sc.gc.ca/dhp-mps/alt_formats/pdf/prodpharma/applic-demande/guide-ld/patmedbrev/pmreg3_mbreg3-eng.pdf

Draft Guidance

27 Oct 2016
How to Pay Fees to Health Products and Food Branch (HPFB)

http://www.hc-sc.gc.ca/dhp-mps/prodpharma/applic-demande/guide-ld/costs-couts/crpay_rcfrais_for-eng.php

Guidance

19 Oct 2016
Post-Notice of Compliance (NOC) Changes: Quality Document

http://www.hc-sc.gc.ca/dhp-mps/prodpharma/applic-demande/guide-ld/postnoc_change_apresac/noc_pn_quality_ac_sa_qualite-eng.php

Guidance

14 Oct 2016
Consultation on the Health Canada Draft Guidance Document: Quality (Chemistry and Manufacturing) Guidance: New Drug Submissions (NDSs) and Abbreviated New Drug Submissions (ANDSs)

http://www.hc-sc.gc.ca/dhp-mps/consultation/drug-medic/qual-ndsands-draft-ebauche-pdnpadn-eng.php

http://www.hc-sc.gc.ca/dhp-mps/consultation/drug-medic/qual-adden-gd-draft-ebauche-ld-eng.php

http://www.hc-sc.gc.ca/dhp-mps/consultation/drug-medic/qual-gloss-term-gd-draft-ebauche-ld-eng.php

http://www.hc-sc.gc.ca/dhp-mps/consultation/drug-medic/cpidce-gd-draft-ebauche-ld-dcipec-eng.php

This consultation was open for comment until December 4, 2016

Draft Guidance

2016/08/31

05 Oct 2016

Updates from Health Canada (Drugs and Biologics)

Type of Update and Link Date Posted
Notice: Mandatory Requirements for using the Common Electronic Submissions Gateway (CESG) 28 Dec 2016
Notice: Final Release: Part I – Health Professional Information and Part II – Scientific Information of the Guidance Document – Product Monograph 09 Dec 2016
Fact Sheet: Biosimilars

 

07 Dec 2016
Register of Innovative drugs

 

02 Dec 2016
Notice – Validation rules for regulatory transactions submitted to Health Canada in the electronic Common Technical Document (eCTD) format 01 Dec 2016
Notice: Release of Draft (Step 2) International Council for Harmonisation (ICH) Guidance: E11(R1): Addendum: Clinical Investigation of Medicinal Products in the Pediatric Population

 

04 Nov 2016
Notice: Release of the revised Post-Notice of Compliance (NOC) Changes – Quality Guidance

 

03 Nov 2016
Notice – Post-Notice of Compliance (NOC) Changes: Notices of Change (Level III) Form

 

03 Nov 2016
Product Monograph Brand Safety Updates

 

19 Oct 2016
This entry was posted in Cato Research, Drug Development, Health Canada, Medical Research, Regulatory Strategy, Regulatory Submissions and tagged , , , . Bookmark the permalink.

Comments are closed.